The impact of the length of total and intravenous systemic antibiotic therapy for the remission of diabetic foot infections

Abstract

ObjectiveWe investigated the impact of the total length of systemic antibiotic therapy (ABT) and its initial intravenous (IV) part on clinical failure (CF) and microbiological failure (MF) in diabetic foot infections (DFIs). MethodsIn this single-center, retrospective, unmatched case-control study, we included DFI episodes treated with a combined surgical-antibiotic approach. ResultsWe included 721 DFI episodes, 537 with osteomyelitis (DFO). CF occurred in 191 (26.5%) and MF in 42 (5.8%) episodes. Multivariate Cox regression analysis showed that a short ABT of 8–21 days (hazard ratio [HR] 0.4; 95% CI 0.2–0.7) was inversely associated with CF. This was also applicable for IV ABT with relatively short durations of 2–7 days (HR 0.5; 95% CI 0.3–0.8) or 8–14 days (HR 0.6; 95% CI 0.4–0.9). We failed to detect a minimal threshold of total or IV ABT predictive for CF or MF. ConclusionsCompared with total ABT of more than 84 days and IV therapy of more than 14 days, shorter total and IV ABT yielded no enhanced risk of CF or MF. Considering the “bias by indication” that is inherent to retrospective DFI studies, the best study design concerning the duration of ABT would be a stratified, prospective randomized trial, which is currently under way in our medical center.